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Abstract
Children represent a significant proportion of the global tuberculosis (TB) burden, and may be 
disproportionately more affected by its most severe clinical manifestations. Currently available 
treatments for pediatric drug-susceptible (DS) and drug-resistant (DR) TB, albeit generally 
effective, are hampered by high pill burden, long duration of treatment, coexistent toxicities, and 
an overall lack of suitable, child-friendly formulations. The complex and burdensome nature of 
administering the existing regimens to treat DS TB also contributes to the rise of DR TB strains. 
Despite the availability and use of these therapies for decades, a dearth of dosing evidence in 
children underscores the importance of sustained efforts for TB drug development to better meet 
the treatment needs of children with TB. Several new TB drugs and regimens with promising 
activity against both DS and DR TB strains have recently entered clinical development and are in 
various phases of clinical evaluation in adults or have received marketing authorization for adults. 
However, initiation of clinical trials to evaluate these drugs in children is often deferred, pending 
the availability of complete safety and efficacy data in adults or after drug approval. This 
document summarizes consensus statements from an international panel of childhood TB opinion 
leaders which support the initiation of evaluation of new TB drugs and regimens in children at 
earlier phases of the TB Drug development cycle.
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INTRODUCTION
TB is a major, but often unrecognized, cause of morbidity and mortality among children in 
the developing world. Current figures probably underestimate the global disease burden, 
with childhood TB cases accounting for an estimated 6% of reported cases, 1 and at least 
double this percentage in highly TB-endemic areas. 2 Underdiagnosis (and thus 
underreporting) is of special concern in younger children who are at greatest risk of disease 
progression following TB exposure and infection, and in whom microbiologic or other 
diagnostic confirmation of both tuberculous infection and disease is most problematic. 3 
HIV infection increases the risk of TB disease and death, particularly in the absence of 
antiretroviral treatment. 4–10 Of further concern is that the number of children with DR-TB 
is increasing globally. 11–16 TB treatment, including treatment for DR-TB, can be effective 
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for children, 17 but is limited by poor service delivery, a lack of child-friendly drug 
formulations, and a scarcity of data on safety, dosing, and drug-drug interactions. 17–22 A 
critical gap persists for the treatment of DR-TB: new drugs and regimens are needed for 
children, and more data are needed to strengthen the evidence base and guide the use of 
existing second-line drugs 18, 23 decrease pediatric TB medicines’ market fragmentation and 
improve access to these drugs. 24 This document, which builds on previous similar 
efforts 25, 26, presents consensus statements from an expert panel to promote strategies for 
the timely collection of evidence on safety and dosing of TB drugs in children to guide 
clinical management and optimize the care of children with TB.
CONSENSUS STATEMENTS PREPARATION
Search strategy and selection criteria
Before the workshop, relevant literature was surveyed (SN, RB2, PJP) to review evidence 
and prepare statements for discussion. The databases we searched included PubMed, 
Medline, Embase with an emphasis on English language papers published during the past 10 
years in peer-reviewed journals. Some older papers were also included if they were judged 
to be important by the authors. Search terms included “TB”, “childhood TB”, “Anti TB 
treatment”, “MDR-TB treatment”, “MDR-TB outcomes”, “Drug Exposure”, 
“Pharmacovigilance”, “clinical trials”, “Drug Development”, “HIV-infected”, 
“Pharmacokinetics”, “Ethics”.
Consensus generation
Expert pediatric TB clinicians, researchers, and opinion leaders were invited to a workshop, 
“Towards Earlier Involvement of Children and Pregnant Women in Trials of New TB 
Drugs”, organized by the National Institutes of Health (NIH) in Bethesda, MD, in May 
2013. The expert Panel’s consensus on pregnant or lactating women is reported separately. 
Members from regulatory agencies were invited to attend as non-voting panelists.
Draft statements were circulated to panelists for review and comment, discussed on 
teleconference calls, revised accordingly and drafts distributed to participants before the 
workshop. During timed discussions, a group consensus approach was used, that included 
modifying the statements in real time based on panelists’ suggested modifications. Edited 
statements underwent panel vote. Voting rules included 2 options: agree or disagree, as 
indicated by a show of hands. Consensus was declared for a statement if ≥75% of panelists 
agreed to the final draft statement. All statements were further reviewed in a final plenary 
workshop session. After the workshop, additional conference calls were held with panelists 
to finalize consensus.
STATE OF RESEARCH ON NEW TB DRUGS IN CHILDREN
Ongoing and planned trials
This is a particularly exciting time in TB drug research. New drugs, many with novel 
mechanisms of action, novel drug combinations and strategies to treat TB are being 
investigated. Clinical trials for DR-TB in adults are currently underway for new 
nitroimidazoles (delamanid, PA-824), oxazolidinones (sutezolid, linezolid, AZD5847), 
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bedaquiline, and clofazimine. 27–30 Some of these drugs have received accelerated approvals 
for marketing. 31–33 Novel combinations that include both new chemical entities and older 
or repurposed drugs are being tested in adults in studies such as ‘REMox’(Rapid Evaluation 
of Moxifloxacin in the treatment of sputum smear positive tuberculosis), the Global Alliance 
for TB Drug Development’s ‘NC002’ (PA-824, moxifloxacin, and pyrazinamide) and 
‘NC003’ (clofazimine, bedaquiline, PA-824 and pyrazinamide) trials, and the ‘STREAM’
(The Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for 
Patients with multidrug-resistant [MDR]-TB) trial. 34–36 Unfortunately, studies in children 
lag significantly behind adult studies, and safety and pharmacokinetic studies to support a 
pediatric indication are currently on-going or planned in children for very few of these novel 
treatments (delamanid and bedaquiline). This lag in developing studies in children is 
reflected in research and development investments for pediatric TB accounting for just two 
percent of the total funding invested in TB research overall 37 but a quarter of the estimated 
need. 38 Figure 1 illustrates main phases in TB drug development and Table 1 summarizes 
relevant TB treatment studies in children, known to the authors.
Ethical considerations
Children are a vulnerable group with limited or developing autonomy and are legally 
disallowed from providing informed consent. Children, therefore, require special measures 
to protect them from exploitation and harm. Many international guidance documents and 
regulations specify acceptable risk/benefit ratios and require that research involving children 
offers a prospect of benefit, or poses minimal risk. 39 An acceptable risk/benefit balance for 
the involvement of children in clinical trials depends not only on the risk/benefit ratio of a 
study for the individual child, but also on the available alternatives and the social value of 
the research 40, which for children depends on the burden of the disease being studied and 
the need for the intervention in that population.
A concern is that involvement of children in research at earlier stages of drug development 
may expose them unnecessarily to investigational drugs with uncertain future and 
undocumented safety risks. Some ethics guidance documents require that children be 
enrolled in research only if the research cannot be conducted in adults. 41 Others propose 
initiating pediatric studies (Phase I or II), particularly in children with serious and life-
threatening diseases who could benefit from the study intervention, after obtaining 
preclinical safety data and evidence of efficacy from adult studies. 42, 43 Both TB in young 
children, 10 and DR-TB in all children, 20, 44 are serious and life-threatening conditions with 
limited treatment options, with affected children potentially further harmed by the dearth of 
data to guide use of existing drugs. Thus, TB drug research can and does, in such instances, 
offer a prospect of direct benefit to children that outweighs the risks of proceeding to 
pediatric trials with relatively incomplete (i.e. before Phase III) adult data. For these reasons, 
the earlier involvement of children in specific TB trials may be ethically justified.
Regulatory environment
Although drug regulatory legislation in both the United States (US) 45 and Europe 46 
similarly provides incentives for the inclusion of children as part of any product’s 
development plan, the requirement for studies in children in an orphan indication differ. In 
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the US, drugs intended to treat TB generally qualify for orphan designation under the orphan 
drug regulations, 47 and inclusion of children in pre-licensure trials is not required. 45 
Similarly, drugs intended to treat TB can enjoy orphan medicinal product status in Europe, 
however no exemption is given for inclusion of children in trials investigating new TB 
therapies, and a pediatric investigation plan has to be agreed with the European Union 
regulators. 48 In South Africa, the Medicines Control Council (MCC) pays special attention 
to the conduct of research in minors, ensuring that clinical trials in TB are consistent with 
the National Health Act. 49 To ensure that prospects of direct benefit accrue to the 
participant, the Act requires that all research be therapeutic; non-therapeutic trials must be 
specifically authorized and deemed to contribute significantly to generalizable knowledge.
SUMMARY OF EXPERT PANEL CONSENSUS
The following sections summarize consensus statements around four main questions and 
topics.
1. What types of drugs or regimens should be prioritized for clinical trials in children?
When considering a new TB drug or regimen for study in children, characteristics 
(preclinical and adult clinical data) that suggest outcomes at least as favorable as established 
alternatives in the study setting should guide the TB drug/regimen selection and 
prioritization. These characteristics include the following: (a) similar or improved efficacy/
effectiveness compared to an available alternative; (b) improved safety/toxicity and 
tolerance profile as compared to a standard regimen; (c) prospect for TB treatment 
shortening or simplification of the administration schedule; (d) prospect for administration 
of a fully oral regimen; (e) fewer drug-drug interactions, especially with antiretroviral drugs; 
and (f) availability in an appropriate formulation for dosing the targeted age group(s).
Development of child-friendly formulations for accurate pediatric dosing is important, and 
planning should be initiated once minimally acceptable adult safety data have been 
constituted, sufficient pharmacokinetic and pharmacodynamics information is available, and 
when at least an efficacious dose range in adults has been established (Phase IIA results are 
available). Care must be taken to investigate tolerability, palatability and formulations (e.g., 
fixed dose combination, dispersible pills, granules, or sprinkles) for children across the 
pediatric age spectrum. However, the development of an appropriate formulation to allow 
accurate pediatric dosing, while preferred, should not delay the initiation of clinical trials in 
children but can be developed in parallel.
When designing trials for new regimens, in addition to the criteria for drug prioritization, the 
practicality and clinical effectiveness of any new drug or regimen needs to be considered. 
Key principles that ensure correct treatment and ease of programmatic use in high-burden 
settings in particular should be followed, and the feasibility for use in resource-limited 
settings (e.g. the need for refrigeration and the shelf-life of a drug) considered. 50 Table 2 
presents the World Health Organization (WHO) classification of existing TB drugs and 
Table 3 briefly summarizes existing information on selected priority TB drugs in children 
including criteria for their prioritization and lists current knowledge gaps.
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2. Which populations of children are among the highest priority for study?
Once sufficient adult safety and efficacy data are available (discussed in the following 
section), it is recommended to initiate pediatric Phase I and II clinical trials. To this end, 
certain pediatric populations should be prioritized based on their medical needs. The greatest 
need for more effective, child-friendly, and less toxic drugs/regimens is in the management 
of children with DR-TB, 20 children in younger age groups 10, 51, 52 and, for preventative 
treatment, in those children exposed to or infected by an index case with DRTB. 53–56 
Studies are particularly essential in children under 2 years of age (with specific inclusion of 
infants) in whom pharmacokinetics may be substantially different compared to older 
children and adults. 57 Children with conditions such as HIV infection or malnutrition that: 
(a) increase their vulnerability to TB, (b) influence the pharmacokinetic profiles of TB 
drugs, or (c) increase the likelihood of drug interactions, are also important populations to 
prioritize for studies. 4, 58–60
Although evaluation of efficacy is not the main objective of studies of new drugs/regimens 
in children, optimizing benefit for and limiting unnecessary risks in children continue to be 
major driving aims of pediatric studies. Therefore, only children with a diagnosis of 
confirmed or probable TB as per published case definitions for DS or DR-TB should be 
enrolled in TB treatment trials. 61–63 Similarly, only children with documented significant 
exposure to DR-TB and evidence of infection as per accepted definitions (e.g., positive 
result from a tuberculin skin test or interferon gamma release assay) should be enrolled in 
TB prevention trials of new drugs/regimens.
3. When can Phase I or II studies be conducted in children, and what data are needed to 
facilitate their inclusion?
Risks from initiating trials of new TB drugs at earlier phases of TB drug development can be 
mitigated when sufficient adult pre-clinical and/or clinical data are available to allow 
adequate evaluation of the risk/benefit ratio. Enrollment of children in TB drug research is 
acceptable when the following are available: (a) results are available from a full range of 
non-clinical studies including repeated dose toxicity studies of appropriate duration in adult 
animals, (b) a complete package of safety pharmacology and genotoxicity studies and 
appropriate juvenile animal toxicity studies are available, and when those results do not 
indicate serious cause for concern; (c) animal and adult human studies (early bactericidal 
activity [EBA] or other appropriate studies) have confirmed anti-Mycobacterium 
tuberculosis (M.tb) activity; (d) data on drug pharmacokinetics and pharmacodynamics in 
adult participants allow for the selection of appropriate pharmacokinetic targets in children 
or, alternatively, an efficacious and safe adult dose has been established (Phase IIB); and (e) 
for HIV-infected children, drug interaction information with antiretroviral drug(s) of interest 
is available from adult studies prior to opening similar studies for the pediatric population(s) 
of interest. Concurrent evaluations of more than one (unapproved) drug in a TB regimen 
may be appropriate when such studies have already been completed in adults and have 
acceptable safety, efficacy, and pharmacokinetic profiles with manageable drug-drug 
interactions. 64
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When the above criteria are met, a smaller safety database or a higher threshold for 
acceptable risk may be acceptable for initiating studies in pediatric groups with the greatest 
medical needs. In most situations, safety data from Phase IIB trials in adults should be 
sufficient to allow for determination of an acceptable risk/ benefit profile for children. 
However, before undertaking pediatric studies, the following steps should ideally be in 
place: development of child-friendly formulations, and a feasible pediatric investigation 
plan. Therefore, TB drug developers should consider preparing for pediatric studies when a 
drug shows promising efficacy and safety in Phase IIA adult trials.
4. What are the relevant elements of clinical trial design?
Investigational approach
General considerations: Efficient and ethical study designs that produce the highest 
achievable quality of evidence should be adopted to determine the doses that are safe and 
achieve pharmacokinetic goals. This will help to limit the number of children exposed to 
experimental doses of a new drug or treatment regimen. Based on developmental 
pharmacokinetic principles, particularly rapid pharmacokinetic changes are expected in the 
first weeks of life, 65 while after 2 years of age, allometric scaling for size will, in the case of 
many drugs, allow prediction of pharmacokinetic targets based on those in adults. However, 
differences are expected between pediatric age groups. Therefore, the following age groups 
are proposed, as a guideline, for pediatric pharmacokinetic evaluations: 0 - < 3 months, 3 - < 
24 months, 2 - < 5 years, 5 - 10 years, and > 10 years of age to adulthood. In most instances, 
novel TB agents should be evaluated in children concurrently receiving appropriate standard 
of care TB treatment. For children with mild disease, initial single agent therapy may be 
considered for pharmacokinetic studies, typically for up to 2 weeks.
Placebo-controlled studies are not generally necessary or helpful in children if the novel TB 
agent has proven efficacy in adult studies and sufficient adult data exists to suggest initial 
safe pediatric dosing. Use of a placebo should only be considered when (a) there is an 
extraordinary scientific need to evaluate complex toxicity and tolerance issues in children; 
(b) when placebo use does not pose a risk of serious harm or risk to trial feasibility; and (c) 
if the research addresses a question that is relevant to health priorities in the countries where 
it is undertaken. 43 Situations where placebo use may be appropriate include when there is 
need to evaluate safety signals for novel therapies or in situations where a high background 
of adverse events from the disease or from co-administered medications is anticipated.
Study outcomes and extrapolation of adult efficacy data: With the scarcity of data for 
drugs and regimens in children, evaluation of a new drug or regimen should preferably 
include the following outcomes: (a) equivalent serum concentrations to those achieved in 
adults at optimal dose including formulations bioequivalence studies, (b) safety and 
tolerability of child-friendly formulations, and when feasible or appropriate (c) time to 
culture conversion, mortality and morbidity data. Extrapolation of adult efficacy data to 
pediatric populations limits the number and size of pediatric trials while allowing efficient 
use of resources. As a result, children can have earlier access to safe, efficacious, and 
evidence-based therapies. Extrapolation is possible when the following three assumptions 
apply: a) the progression of disease is sufficiently similar in adults and the pediatric 
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populations; b) response to intervention is similar in adults and the pediatric populations 
and, c) adult and pediatric populations have a similar exposure-response relationship. (See 
Figure 2) 66–68 Thus, efficacy studies in children for new drugs for intrathoracic TB, may 
not be necessary to allow for pediatric labeling. Similar response to treatment and exposure-
response relationships in adults and children can be assumed for intrathoracic TB. However, 
efficacy studies may be needed for extrathoracic forms of TB and prevention studies in 
children.
Enrollment strategies: Although sometimes cited as an important safety protection, 69 
enrollment strategies using sequential age de-escalation are not currently required by any 
regulatory body and delay drug evaluation in the youngest age groups. 70 If the TB drug to 
be evaluated in children does not exhibit any significant safety signals in pre-clinical and 
adult clinical studies, pediatric studies should be allowed to proceed directly to concurrent 
evaluation across all pediatric age groups, to the extent that appropriate formulations are 
available. Particular emphasis should be placed on inclusion of the youngest children. 
Enrollment by sequential age de-escalation should be used only rarely, such as when 
specific safety or pharmacokinetic concerns that warrant testing older children before 
proceeding to younger children are identified. Sequential enrollment of age cohorts may 
actually raise ethical concerns by delaying collection of critical pharmacokinetic and safety 
data in the age groups that are most likely to benefit from a new agent or regimen.
Regardless of the approach used, sufficient evaluable subjects within each age cohort must 
be included to strengthen the quality of evidence generated. Furthermore, and to the extent 
possible, Phase IIB and later phase studies in adults should be designed to enroll children 
aged > 10 years, who are expected to have TB disease presentations similar to adults and are 
able to routinely provide sputum specimens due to adult type intrathoracic TB disease. 
Weight (and body surface area) differences within this group should be taken into account 
when establishing a- correct dose. Experts in studies of adolescents should be available to 
the investigators, and safeguards for protection of pediatric participants should be in place. 
Alternatively, if no expectation exists that the drug may interfere with progression through 
puberty or have a different safety profile in adolescents, the drug should be licensed for use 
in that age group without waiting for specific adolescent studies.
Dosing approach: Pharmacokinetic evaluation of single-dose administration of new drugs 
should be considered as a first step to inform multiple-dose pharmacokinetic studies; this 
approach has the potential to minimize risks of unwanted drug exposure. Alternatively, 
multiple dosing in a mini-cohort (i.e., using an initial sample size of no more than 3–6 
children) can be used initially to provide preliminary safety and pharmacokinetic data while 
exposing fewer children. Subsequently, a final recommended dose may be established using 
a larger cohort. Modeling and simulation should be used to predict initial dosing in children 
for each age category. Selection of the initial dose in children can be informed by semi-
mechanistic models adjusted for weight and other age-related changes such as volume of 
distribution, metabolizing enzyme maturation, and rate of drug excretion. As they become 
more accurate, physiologic-based pharmacokinetic models may increasingly contribute to 
initial dose selection. 71 Both safety and pharmacokinetic data from children should be 
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incorporated into these models as soon as they become available, and should be used to 
improve subsequent dose prediction in successive cohorts of children. Real-time drug 
concentration analysis in individual study participants and multiple interim analyses of drug 
exposures in small cohorts within studies allow reduction of risk through rapid dose 
adjustment in individuals and cohorts.
Pharmacokinetic sampling strategies: Approaches that include methods to minimize 
pharmacokinetic sampling and sample volumes, rapid analysis of pharmacokinetic results to 
inform more accurate dosing in adaptively designed studies, and stratification by age, 
weight, and drug formulation schemas should be used when appropriate. Semi-mechanistic 
pharmacokinetic modeling using a population approach can enable opportunistic sampling 
and facilitate the use of variable sampling times and relatively sparse sampling schedules. 
The efficiency of this approach is enhanced further by the use of optimal sampling designs 
based on knowledge of the drug’s pharmacokinetics, limiting the number of blood samples 
needed from each child. Special attention must be paid to the volume of blood sampled and 
the timing of samples in very young children.
Additional design considerations: In order to guide dose adjustments, important drug-drug 
interactions should be specifically studied in young children receiving TB treatment. The 
magnitude of drug-drug interactions in this age group may not be predicted by either adult 
studies or other pediatric age cohorts. As with adults, children should be recruited from 
diverse racial and ethnic backgrounds to explore relevant pharmacogenomic differences. 72 
Safety and adverse event data should be disaggregated and analyzed by age group. Data 
pooling can be used to generate models from diverse sources. Mechanisms using similar 
study designs (as appropriate) and standardized data collection forms and procedures should 
be supported to facilitate both collaborative data sharing, combined analyses across studies 
and incorporation into models. Children aged 0–3 months usually benefit from specific 
pharmacokinetic and safety evaluations. Studies should plan to extend duration of drug 
treatment in children who tolerate the drug (and experience no safety issues), if it is 
expected to add benefit to the standard of care; however the duration should not exceed 
length of treatment from adult studies. These methods may increase the prospect of direct 
benefit from the intervention and allow for collection of extended safety data and limited 
treatment response data with more prolonged exposure.
Safety monitoring and long term follow up
Safety monitoring principles: Due to major biological differences between children and 
adults, adverse event (AE) profiles and drug interactions that occur in pediatric patients may 
not be exactly as predicted by adult studies. Depending on the drug(s) being investigated or 
anticipated AEs, initial dosing in an in-patient setting or other intensely monitored study 
setting may be warranted. Special monitoring (e.g. EKG monitoring or other specific 
laboratory measurements) may/may not be needed if data from adults do not suggest any 
specific associated toxicity. Passive reporting should be used only when safety parameters of 
the agent have been well defined in children. Caregivers should be carefully instructed and 
encouraged to promptly report observed signs and symptoms to investigators. Establishment 
of independent safety monitoring committees (SMC), which include experts in pediatric 
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pharmacology, pediatric TB experts, researchers with special experience in pediatric trials, 
or other specialists as needed, can provide additional protection.
Participant long term follow-up: The need for long-term follow-up for specific 
populations and for particular study agents should be given special consideration and should 
be adapted to settings where the study is conducted and where the drug will be used after 
registration. In addition, while the safety profile from adult trials has relevance for children 
it may be less helpful when predicting late adverse effects on growth, development and 
maturation. Hearing loss for example, a known potential complication of aminoglycoside 
use was reported in 24% of children with DR-TB treated with an aminoglycoside, much 
higher than that seen in adults, with several patients continuing to have progression of 
hearing loss months after discontinuation of medication. 19
Long-term follow up and/or drug registry and surveillance data, may be needed to determine 
possible late effects on skeletal, behavioral, cognitive, sexual, and immune developmental 
maturation. The duration of follow-up can be drug-specific, based on any signal or concern 
uncovered during pre-clinical studies or in earlier phase studies in adults. In studies for DR-
TB in children, at least 24 months follow-up after treatment completion should be 
considered routine, since toxicity for some agents is duration-dependent, and the risk of 
disease relapse is greatest within the first year after treatment completion. Lastly, post 
marketing surveillance and patient registries may provide additional safety information that 
could not be detected from the limited pediatric exposures from clinical trials. In particular, 
post marketing pharmacovigilance activities, because of the greater cumulative drug 
exposures in the post marketing safety database, could detect rare, serious and/or patient-
specific AEs.
FURTHER ISSUES TO BE ADDRESSED
Improving the understanding of TB treatment in children requires participation of all 
stakeholders involved in TB drug research design and implementation. Regulators should 
evaluate the existing options to harmonize requirements and streamline processes for 
pediatric drug development. For new TB drugs, regulators should require and agree upon a 
formal, time-bound pediatric development plan that includes the development of child-
friendly formulations earlier in the drug development cycle. Investigators are encouraged to 
include children as soon as possible in studies, with appropriate safeguards, and should 
prioritize research questions most in need of answers, as described earlier. Drug companies/
sponsors should initiate pediatric studies at the time points suggested previously, even if not 
a specific regulatory requirement. Sponsors should make all relevant information, not just 
safety and dosing information, available to facilitate further evaluation by research consortia 
and other non-commercial research bodies, particularly when multiple new compounds may 
be utilized in combination. Sponsors, in conjunction with investigators and community 
groups, should encourage the inclusion of children > 10 years in initial treatment trials in 
adults. Advocates should call for clear, harmonized guidance from regulators including 
requests for: early development of child-friendly drug formulations, the inclusion of children 
in drug safety, dosing, and efficacy trials, and better understanding of global and local 
pediatric TB disease burdens. They will also need to advocate for increased funding of 
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pediatric TB research. 37, 73 New mechanisms of collaboration should be developed among 
all these stakeholders, such as the formation of a standing group to facilitate the earliest 
possible sharing of data and information on new TB drugs (to help determine when they 
should enter trials), make coordinated decisions and plans, enable harmonized approaches 
and address priorities on a consistent, ongoing basis, while minimizing resource duplication.
CONCLUSION
The scarcity of research of TB treatment in children represents a critical gap in global efforts 
to lessen the burden of TB infection and disease and to control the spread of drug resistance. 
Children, despite their increased vulnerability to TB, are subject to TB underreporting, and 
in some settings are at highest risk for exposure, infection and serious TB disease. 
Extrapolating from the adult treatment experience and adult clinical data may be inadequate 
for post licensure use of TB drugs in children, even if adult information suggests an 
acceptable risk/benefit ratio for children. Inclusion of children into studies should occur at 
the early phases of TB drug development and be an integral part of the clinical development 
plan, rather than as a post-approval activity. The consensus presented in this paper addresses 
ethical, regulatory, and methodological considerations that take into account the interests of 
and features unique to children, and promotes bold concepts that should accelerate the 
involvement of children in safe, ethical trials of new TB drugs and at earlier stages of the 
drug development cycle.
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Figure 1. TB Drug Development phases
Reproduced with permission 74
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Figure 2. Pediatric studies decision tree
Reproduced from: http://www.fda.gov.ezproxy.nihlibrary.nih.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf. Abbreviations: 
PK/PD: pharmacokinetics/pharmacodynamics; ER: exposure-response
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Table 1
On-going and planned studies in children (current as of December 2013)
Study Sponsor Status Endpoint
Pharmacokinetics of first-and second-line agents in children with DS-
TB and DR-TB
NIH on-going PK and safety
Pharmacokinetics of delamanid in children Otsuka on-going PK, safety
Pharmacokinetics of bedaquiline in children Janssen, IMPAACT1 Planned PK, safety
SHINE –Treatment shortening in children with paucibacillary TB British MRC2/ DFID3/
Wellcome Trust
Planned Efficacy, safety, PK
Pharmacokinetics of first-line agents in infants TB Alliance Planned PK
Rifapentine+isoniazid in children in LTBI5 TBTC4 Planned PK, safety
Levofloxacin and isoniazid in children exposed to DR-TB IMPAACT Planned Efficacy
1
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
2
Medical Research Council
3
Drugs For Neglected Infectious Diseases
4
Tuberculosis Trials Consortium
5
Latent TB Infection
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Table 2
WHO grouping of drugs used for DR-TB
Group Drugs (abbreviations)
Group 1:
First-line oral agents
pyrazinamide (Z)
ethambutol (E)
rifabutin (Rfb)
Group 2:
Injectable agents
kanamycin (Km)
amikacin (Am)
capreomycin (Cm)
streptomycin (S)
Group 3:
Fluoroquinolones
levofloxacin (Lfx)
moxifloxacin (Mfx)
ofloxacin (Ofx)
Group 4:
Oral bacteriostatic second-line
Agents
para-aminosalicylic acid (PAS)
cycloserine (Cs)
terizidone (Trd)
ethionamide (Eto)
protionamide (Pto)
Group 5:
Agents with unclear role in
treatment of drug resistant-TB
clofazimine (Cfz)
linezolid (Lzd)
amoxicillin/clavulanate (Amx/Clv)
thioacetazone (Thz)
imipenem/cilastatin (Ipm/Cln)v high-dose isoniazid (high-dose H)b
clarithromycin (Clr)
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